Staging the severity of myocardial damage in aortic stenosis: a new addition to solving the puzzle
European Heart Journal - Cardiovascular Imaging · 23.11.2023 · 24 (12) · 1618-1619
DOI: 10.1093/ehjci/jead165 ↗Kurz gefasst
Editorial in der Zeitschrift European Heart Journal - Cardiovascular Imaging, online erschienen am 07.07.2023. Verfasst von Leyla Elif Sade und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh Medical Center, Heart and Vascular Institute, 200 Lothrop Street, Ste: E354.2, Pittsburgh, PA 15232, USA. Hauptthemen laut MEDLINE: Heart, Aortic Valve Stenosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
This editorial refers to ‘Redefining cardiac damage staging in aortic stenosis: the value of GLS and RVAc’, by E. Gutierrez-Ortiz et al., https://doi.org/10.1093/ehjci/jead140. Technical advances and improved expertise have increased the success and the safety of aortic valve interventions and expanded the treatment option to patients with moderate aortic stenosis (AS) or asymptomatic patients with severe AS. The main driver of a paradigm shift towards a more aggressive and earlier intervention was the understanding of the non-benign nature of these conditions that did not meet the classical criteria for aortic valve replacement (AVR). Furthermore, the extent of cardiac damage was found to be a stronger predictor of adverse outcomes after AVR than the aortic valve area and the peak velocity.1,2 The evidence underlined that the correction of the haemodynamic burden by AVR was not enough to achieve a long-term favourable mortality reduction, unless non-valvular cardiac damage was addressed in a timely manner. Hence, a staging system to quantify the extent of cardiac damage has been introduced with the PARTNER (Placement of Aortic Transcatheter Valves) trial for the first time and validated in large independent cohorts.1 In this issue of the European Heart Journal Cardiovascular Imaging, Eva Gutierrez-Ortiz E. et al.3 reported their data which is an important addition to the previous staging models of the severity of cardiac damage in AS. The authors should be congratulated on their careful and important analysis conducted in a large series of patients with severe symptomatic AS undergoing transcutaneous aortic valve replacement (TAVR) that showed higher sensitivity and stronger predictive value for all-cause mortality as compared to previous models. In all, 496 patients from a prospective registry were included. To create the new staging model, they used the variables clinically relevant and statistically significant in the univariable analysis. They defined the best cut off values and dichotomized the independent variables when testing their predictive value in their model. Among the independent variables, chronic kidney disease, logistic Euroscore, left ventricular (LV) ejection fraction, global longitudinal strain (GLS), mitral regurgitation (MR), systolic pulmonary artery pressure (sPAP), tricuspid annular plane systolic excursion (TAPSE), and TAPSE/sPAP (variable estimating right ventricular–pulmonary arterial pressure coupling) were found to be predictors of mortality on univariate analyses. Unfortunately, the multivariate analysis did not include all the univariate variables with P < 0.1 but included only the GLS, MR, and TAPSE/sPAP which may generate some bias. Parameters pertaining to the AS severity were not different between survivors and non-survivors as expected because the cohort included only patients with severe AS. Their model included LV GLS ≥ −17%, significant MR, and TAPSE/sPAP < 0.35. In addition, to the concern about selection bias of the independent variables, 88.6% of significant MR were degenerative which makes arguable the use of MR in the model as a marker of LV damage secondary to AS. Four different stages of the new model were developed using LV-GLS, MR, and TAPSE/sPAP. The area under the ROC curve of the model to predict mortality was 0.66 (95% confidence interval 0.63–0.76), yet the predictive performance of the new model was superior to the previously published models.1,4 Of note, this predictive performance is justified based on the best fit cut offs in the derivation cohort that needs to be taken with some consideration unless validated in independent cohorts. In the population studied, mortality after TAVR was found to be mostly due to non-cardiac causes which confirms the crucial effect of unloading the LV in severe AS to protect from CV mortality. Meanwhile, another question comes to mind: What is the benefit of risk stratifying patients with severe symptomatic AS with the aim to optimizing their outcome? On the other hand, insightful data can be obtained by risk prediction models in patients with asymptomatic severe AS or in patients with moderate AS so that the intervention to relieve the haemodynamic load can be selectively prioritized. The TAVR UNLOAD (Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure; NCT02661451) trial is expected to shed light on these thoughts. Improved patient selection, optimizing the timing of intervention by means of parameters of broad acceptance, simple for acquisition is highly desirable. However, the challenge is that the vast majority of the patients undergoing TAVR are elderly with significant comorbidities. The presumed strong relationship between the AS and the myocardial damage is compelling, but not straightforward. Indeed, demographic characteristics and important co-morbidities such as hypertension, chronic obstructive pulmonary disease, diabetes mellitus, cardiac amyloidosis, chronic kidney disease, atrial fibrillation, and coronary artery disease contribute to myocardial damage (Figure 1). So far, studies (many of them being retrospective) managed this issue by adopting adjusted cox regression analysis to determine the independent association between the AS and the outcome. However, whether providing AVR or TAVR to the so-called high-risk population because of myocardial damage would improve the outcome needs to be tested by randomized trials because the relief of AS may incompletely translate into outcome benefit in the presence of co-morbidities which is also reflected by the results of the present study. Interplay between AS and myocardial damage. COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EF, ejection fraction; GLS, global longitudinal strain; LA, left atrium; LV, left ventricle; MR, mitral regurgitation; RV, right ventricle; TR, tricuspid regurgitation. In addition to the effect of comorbidities on prognostication, many other factors have been shown to be of prognostic relevance including atrial fibrillation, mechanical dispersion, myocardial fibrosis, valvular inflammation, elevated biomarkers, intraventricular electrical conduction delays, blocks, tricuspid regurgitation, and peak vO2 consumption. The complex interplay of these parameters can be best computed with the use of machine learning techniques in the future to reach a holistic approach to risk stratification. Nevertheless, moving beyond the LV ejection fraction and integrating the right ventricular (RV) function was an important step forward that increased the sensitivity of the staging system to identify patients at increased risk of death after TAVR. Eva Gutierrez-Ortiz et al.3 extended the concept by including a more robust recent parameter which is the TAPSE/sPAP within the staging model as a means of RV–pulmonary artery coupling function.5 Indeed, even though the role of RV function has been recognized for its prognostic value in patients undergoing TAVR, its quantification remained challenging.6 Earlier studies that incorporated RV function into the staging of AS evaluated RV function either visually or by TAPSE. Quantitative assessment of RV function by means of longitudinal speckle tracking strain, fractional area change, and 3D volumes by echocardiography is beginning to gain wider acceptance. Yet, none of these parameters stands as a single prognosticator but rather multi-parametric evaluation seems more reliable and more insightful for clinical judgment about the RV function. Not only its peculiar geometry but also its critical dependence on loading conditions with complex mechanisms of transition from compensation to decompensation makes it mandatory to consider the interaction between different metrics of RV function. In that regard, afterload-adjusted measurements of RV longitudinal function have begun to gain wider acceptance. One such parameter is TAPSE/sPAP, that the authors included in their staging system deserves recognition. Finally, reclassifying AS is a multi-faceted task. It is difficult to isolate the valvular insult to the LV and upstream structures from patient characteristics and comorbidities. Further research is awaited to determine whether reclassification or staging of the disease severity will help to improve the outcome. In those with severe AS, correcting the haemodynamic load is expected to impact the outcome favourably regardless of myocardial damage. However, in those with moderate AS, cofactors may be the drivers of myocardial damage and the haemodynamic relief of stenosis may not completely predict the extent of improvements in outcome, Hence, staging of myocardial damage will play an important role. None declared. No new data were generated or analysed in support of this research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of Pittsburgh Medical Center, Heart and Vascular Institute, 200 Lothrop Street, Ste: E354.2, Pittsburgh, PA 15232, USA.
- Penn State University College of Medicine, 500 University Drive Hershey, Hershey, PA 17033, USA.
ORCID-Profile: Leyla Elif Sade
Zitieren
APA
Sade, L. E., & Gorcsan, J. (2023). Staging the severity of myocardial damage in aortic stenosis: a new addition to solving the puzzle. European Heart Journal - Cardiovascular Imaging, 24(12), 1618-1619. https://doi.org/10.1093/ehjci/jead165
Vancouver
Sade LE, Gorcsan J. Staging the severity of myocardial damage in aortic stenosis: a new addition to solving the puzzle. European Heart Journal - Cardiovascular Imaging. 2023;24(12):1618-1619. doi:10.1093/ehjci/jead165
BibTeX
@article{Sade2023,
author = {Sade, Leyla Elif and Gorcsan, John},
title = {Staging the severity of myocardial damage in aortic stenosis: a new addition to solving the puzzle},
journal = {European Heart Journal - Cardiovascular Imaging},
year = {2023},
volume = {24},
number = {12},
pages = {1618--1619},
doi = {10.1093/ehjci/jead165}
}
EUVIMED